The DOI matches its OpenAlex record; 41 of the 41 references it cites were found in a registry or an index.
Hydroxyurea induces fetal hemoglobin by the nitric oxide–dependent activation of soluble guanylyl cyclase
Open accessAbstract
Hydroxyurea treatment of patients with sickle-cell disease increases fetal hemoglobin (HbF), which reduces hemoglobin S polymerization and clinical complications. Despite its use in the treatment of myeloproliferative diseases for over 30 years, its mechanism of action remains uncertain. Recent studies have demonstrated that hydroxyurea generates the nitric oxide (NO) radical in vivo, and we therefore hypothesized that NO-donor properties might determine the hemoglobin phenotype. We treated both K562 erythroleukemic cells and human erythroid progenitor cells with S-nitrosocysteine (CysNO), an NO donor, and found similar dose- and time-dependent induction of gamma-globin mRNA and HbF protein as we observed with hydroxyurea. Both hydroxyurea and CysNO increased cGMP levels, and the guanylyl cyclase inhibitors ODQ, NS 2028, and LY 83,538 abolished both the hydroxyurea- and CysNO-induced gamma-globin expression. These data provide strong evidence for an NO-derived mechanism for HbF induction by hydroxyurea and suggest possibilities for therapies based on NO-releasing or -potentiating agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340 · cited 2×
“Nonstandard abbreviations used: fetal hemoglobin (HbF); S-nitrosocysteine (CysNO); soluble guanylyl cyclase (sGC); (Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1ium-1,2-diolate (DETA-NONOate); stem cell factor (SCF); 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ); 4H-8-bromo-1,2,4-oxadiazolo[3,4-d]benz[b]…”
BackgroundMethodGuanylate cyclase and the ⋅NO/cGMP signaling pathway
Denninger, J. W., & Marletta, M. A. (1999) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(99)00024-9 · Cited by 1,040
Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
Platt, O. S., Orkin, S. H., Dover, G., Beardsley, G. P., Miller, B., & Nathan, D. G. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111464 · Cited by 535
Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide.
Kwon, N. S., Stuehr, D. J., & Nathan, C. F. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.4.761 · Cited by 425
Inhibition of ribonucleoside diphosphate reductase by hydroxyurea.
Krakoff, I. H., Brown, N. C., & Reichard, P. A. (1968) · PubMed · Cited by 422
Mechanism of action of hydroxyurea.
Yarbro, J. W. (1992) · PubMed · Cited by 407
Proliferation and maturation of human erythroid progenitors in liquid culture
Fibach, E., Manor, D., Oppenheim, A., & Rachmilewitz, E. (1989) · Blood · doi:10.1182/blood.v73.1.100.100 · Cited by 271
Rodgers, G. P., Dover, G. J., Uyesaka, N., Noguchi, C. T., Schechter, A. N., & Nienhuis, A. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280201 · Cited by 242
Self-citationNitric oxide donor properties of hydroxyurea in patients with sickle cell disease
Gladwin, M. T., Shelhamer, J. H., Ognibene, F. P., Pease‐Fye, M. E., Nichols, J. S., Link, B., Patel, D. B., Jankowski, M. A., Pannell, L. K., Schechter, A. N., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03274.x · Cited by 234
Self-citationHydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia
Charache, S., Dover, G., Moyer, M., & Moore, J. (1987) · Blood · doi:10.1182/blood.v69.1.109.109 · Cited by 204
Research works printed but not linked: 15
- Charache, 1997, Semin. Hematol., 34, 15
- Stoeckert, 1994, Exp. Hematol., 22, 278
- Erard, 1981, Blood., 58, 1236, 10.1182/blood.V58.6.1236.1236 · doi:10.1182/blood.v58.6.1236.1236
- Xu, 1998, Exp. Hematol., 26, 265
- Krakoff, 1968, Cancer Res., 28, 1559
- Yarbro, 1992, Semin. Oncol., 19, 1
- Bundy, 1999, Am. J. Physiol., 277, H1799
- 10.1073/pnas.041599798 · doi:10.1073/pnas.041599798
- Kwan, 1990, Clin. Chem., 36, 607, 10.1093/clinchem/36.4.607 · doi:10.1093/clinchem/36.4.607
- 10.1002/(SICI)1096-8652(199712)56:4<252::AID-AJH10>3.0.CO;2-B · doi:10.1002/(sici)1096-8652(199712)56:4<252::aid-ajh10>3.0.co;2-b
- 10.1074/jbc.274.14.9489 · doi:10.1074/jbc.274.14.9489
- Adunyah, 1995, Biochim. Biophys. Acta., 1263, 123, 10.1016/0167-4781(95)00079-V · doi:10.1016/0167-4781(95)00079-v
- Kim, 2000, Biochim. Biophys. Acta., 1496, 277, 10.1016/S0167-4889(00)00026-4 · doi:10.1016/s0167-4889(00)00026-4
- Chen, 2000, Cell. Mol. Biol. (Noisy-le-grand)., 46, 609
- Park, 2001, Cell Growth Differ., 12, 481
Cited by
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Self-citationThe Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic Vasculopathy
HEBBEL, R. P., OSAROGIAGBON, R., & KAUL, D. (2004) · Microcirculation · doi:10.1080/10739680490278402 · Cited by 463
Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E. (2010) · Blood · doi:10.1182/blood-2009-05-221333 · Cited by 430
“3) Reticulocyte, % 10 (1-40) 6* (1-23) 7* (1-35) 6* (1-18) Bilirubin, mg/dL 1.”
Zhang, D., Xu, C., Manwani, D., & Frenette, P. S. (2016) · Blood · doi:10.1182/blood-2015-09-618538 · Cited by 413
Sickle cell disease: old discoveries, new concepts, and future promise
Frenette, P. S., & Atweh, G. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30920 · Cited by 400
How I use hydroxyurea to treat young patients with sickle cell anemia
Ware, R. E. (2010) · Blood · doi:10.1182/blood-2009-04-146852 · Cited by 396
Hydroxyurea for the Treatment of Sickle Cell Anemia
Platt, O. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0708272 · Cited by 357
Predicting clinical severity in sickle cell anaemia
Steinberg, M. H. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05411.x · Cited by 321
Hydroxyurea therapy for sickle cell anemia
McGann, P. T., & Ware, R. E. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1088827 · Cited by 316
Steinberg, M. H. (2008) · The Scientific World JOURNAL · doi:10.1100/tsw.2008.157 · Cited by 293
Sickle Red Cell–Endothelium Interactions
KAUL, D. K., FINNEGAN, E., & BARABINO, G. A. (2009) · Microcirculation · doi:10.1080/10739680802279394 · Cited by 208
Structure-Function Relations of Human Hemoglobins
Marengo-Rowe, A. J. (2006) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2006.11928171 · Cited by 179
Hsieh, M. M., Linde, N. S., Wynter, A., Metzger, M., Wong, C., Langsetmo, I., Lin, A., Smith, R., Rodgers, G. P., Donahue, R. E., et al. (2007) · Blood · doi:10.1182/blood-2007-02-073254 · Cited by 171
Self-citationThe Perfusion Paradox and Vascular Instability in Sickle Cell Disease
NATH, K. A., KATUSIC, Z. S., & GLADWIN, M. T. (2004) · Microcirculation · doi:10.1080/10739680490278592 · Cited by 102
Self-citationMolecular therapies in β‐thalassaemia
Quek, L., & Thein, S. L. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06408.x · Cited by 88
Khandros, E., Huang, P., Peslak, S. A., Sharma, M., Abdulmalik, O., Giardine, B. M., Zhang, Z., Keller, C. A., Hardison, R. C., & Blobel, G. A. (2020) · Blood · doi:10.1182/blood.2020005058 · Cited by 40
Chronic administration of hydroxyurea (HU) benefits caucasian patients with sickle-beta thalassemia
Di Maggio, R., Hsieh, M., Zhao, X., Calvaruso, G., Rigano, P., Renda, D., Tisdale, J., & Maggio, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030681 · Cited by 12
Metadata
- Authors
- Čokić, V. P., Smith, R. D., Beleslin‐Čokić, B. B., Njoroge, J. M., Miller, J. L., Gladwin, M. T., & Schechter, A. N.
- Venue
- Journal of Clinical Investigation
- Published
- 2003-01-15
- Volume
- 111
- Issue
- 2
- Pages
- 231-239
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4249969224
- Cited by
- 375
- References
- 41
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.